| 1380 |
National Cancer Institute |
Html |
en |
Colorectal Cancer Prevention (PDQ®)–Health Professional Version |
Expert-reviewed information summary about factors that may influence the risk of developing colorectal cancer and about research aimed at the prevention of this disease. |
| colon cancer death | 0.503164 |
| colorectal adenoma chemoprevention | 0.469587 |
| mg/day ASA group | 0.474963 |
| Engl J Med | 0.695761 |
| colorectal cancer risk | 0.569497 |
| American Cancer Society | 0.478754 |
| cancer prevention study | 0.51311 |
| Br J Cancer | 0.490702 |
| case-control study | 0.528084 |
| CRC mortality rates | 0.469166 |
| Ann Intern Med | 0.669327 |
| Int J Cancer | 0.468816 |
| colorectal cancer | 0.947004 |
| fatal colorectal cancer | 0.499741 |
| advanced colorectal adenomas | 0.4802 |
| colon cancer prevention | 0.492834 |
| CRC incidence | 0.472239 |
| Natl Cancer Inst | 0.758173 |
| human colon cancer | 0.480578 |
| hereditary nonpolyposis colorectal | 0.489202 |
| distal colon cancer | 0.492725 |
| colorectal adenomatous polyps | 0.518043 |
| colorectal adenoma prevention | 0.476577 |
| long-term cancer incidence | 0.468066 |
| familial adenomatous polyposis | 0.503867 |
|
| et al. | 0.597227 |
| familial colorectal cancer | 0.51297 |
| large bowel cancer | 0.489321 |
| colorectal adenomas | 0.590599 |
| previous colorectal cancer | 0.507755 |
| nonpolyposis colorectal cancer | 0.531539 |
| cohort study | 0.504026 |
| Cancer Epidemiol Biomarkers | 0.584507 |
| hereditary colon cancer | 0.485595 |
| fatal colon cancer | 0.501384 |
| PUBMED Abstract | 0.577579 |
| CRC mortality | 0.486759 |
| Health Study | 0.488018 |
| National Cancer Institute | 0.488273 |
| Epidemiol Biomarkers Prev | 0.558059 |
| colorectal cancer incidence | 0.562507 |
| colorectal cancer disparities | 0.516267 |
| common colorectal cancer | 0.511542 |
| colorectal cancer rates | 0.517039 |
| colon cancer | 0.785918 |
| Abstract | 0.678628 |
| colon cancer risk | 0.507338 |
| in-trial cancer deaths | 0.471053 |
| colorectal cancer mortality | 0.563581 |
|
CLICK HERE |
| 1394 |
National Cancer Institute |
Html |
en |
Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of pancreatic neuroendocrine tumors (islet cell tumors). |
| patient selection factors | 0.438228 |
| tumor cell types | 0.413939 |
| functional tumors | 0.556939 |
| slow-growing tumors | 0.428195 |
| pituitary tumors | 0.418826 |
| functional pancreatic neuroendocrine | 0.426256 |
| islet cell tumors | 0.811481 |
| preoperative dual-phase thin-section | 0.348132 |
| bone metastases | 0.398217 |
| islet cell cancers | 0.399777 |
| distinctive metabolic effects | 0.341484 |
| secondary endocrine tumors | 0.452606 |
| liver metastases | 0.990586 |
| unresectable liver metastases | 0.497768 |
| endocrine pancreas glands | 0.386 |
| metastatic disease | 0.427564 |
| sporadic islet cell | 0.397131 |
| resectable liver metastases | 0.506505 |
| venous sampling | 0.390094 |
| surgical resection series | 0.389796 |
| visible liver metastases | 0.615044 |
| liver neuroendocrine metastases | 0.512043 |
| individual tumors | 0.388972 |
| progressive pancreatic NETs | 0.411807 |
| clinical manifestations | 0.349816 |
|
| percutaneous alcohol ablation | 0.339566 |
| antihormonal pharmacologic therapy | 0.339279 |
| conventional imaging techniques | 0.33881 |
| radiofrequency ablation | 0.342021 |
| pancreatic resection | 0.466639 |
| pancreatic islets | 0.36916 |
| ulcer-producing Zollinger-Ellison syndrome | 0.354188 |
| somatostatin-receptor scintigraphy | 0.356211 |
| slow-growing metastatic islet | 0.423125 |
| pancreatic NETs | 0.575547 |
| technically demanding tests | 0.350314 |
| multiple endocrine neoplasia | 0.362304 |
| retrospective case series | 0.340498 |
| hormonally functional tumors | 0.47568 |
| tumor suppressor gene | 0.392672 |
| pancreatic islet cell | 0.465855 |
| overall tumor burden | 0.363718 |
| grossly visible liver | 0.505977 |
| MEN-1 syndrome | 0.346786 |
| pancreatic neuroendocrine tumors | 0.701933 |
| liver resection | 0.37949 |
| arterial stimulation | 0.345171 |
| common exocrine adenocarcinomas | 0.348715 |
| preoperative localization studies | 0.4603 |
|
CLICK HERE |
| 1447 |
National Cancer Institute |
Html |
null |
Unusual Cancers of Childhood Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of unusual cancers of childhood such as cancers of the head and neck, chest, abdomen, reproductive system, skin, and others. |
|
|
CLICK HERE |
| 1611 |
National Cancer Institute |
Html |
en |
Late Effects of Treatment for Childhood Cancer (PDQ®)–Health Professional Version |
Serious, disabling, and life-threatening chronic health conditions adversely affect the health of aging childhood cancer survivors. Learn about the cardiovascular, cognitive, psychosocial, digestive, endocrine, immune, musculoskeletal, reproductive, and urinary late effects and subsequent neoplasms that contribute to a high burden of morbidity in childhood cancer survivors. |
| adult cancer survivors | 0.344142 |
| childhood leukemia survivors | 0.307057 |
| Childhood Cancer Guideline | 0.302298 |
| childhood cancer therapy | 0.296791 |
| long-term cancer survivors | 0.295333 |
| childhood cancer survivors | 0.499567 |
| Engl J Med | 0.269755 |
| Br J Cancer | 0.261959 |
| Cancer Survivor cohort | 0.269169 |
| Int J Cancer | 0.266011 |
| Ann Intern Med | 0.263377 |
| 5-year survivors | 0.295172 |
| cancer survivors research | 0.286942 |
| Radiat Oncol Biol | 0.277048 |
| breast cancer surveillance | 0.269328 |
| adult survivors | 0.315122 |
| Hudson MM | 0.309712 |
| young adult cancer | 0.340977 |
| British Childhood Cancer | 0.326521 |
| Natl Cancer Inst | 0.402086 |
| survivor study cohort | 0.273371 |
| Clin Cancer Res | 0.263669 |
| Irradiated Childhood Cancer | 0.298512 |
| childhood cancer | 0.912384 |
| cancer survivor study | 0.693286 |
|
| et al. | 0.431618 |
| late effects | 0.3275 |
| long-term survivors | 0.333244 |
| cohort study | 0.263432 |
| Cancer Epidemiol Biomarkers | 0.265429 |
| pediatric cancer survivors | 0.286679 |
| PUBMED Abstract | 0.35078 |
| Pediatr Blood Cancer | 0.447984 |
| radiation-induced breast cancer | 0.26406 |
| breast cancer risk | 0.280733 |
| Abstract | 0.467444 |
| Clin Oncol | 0.515912 |
| breast cancer | 0.391476 |
| Oncol Biol Phys | 0.278259 |
| childhood cancer survivor | 0.771953 |
| Cancer Guideline Harmonization | 0.260525 |
| young cancer survivors | 0.275759 |
| childhood cancer registry | 0.291062 |
| long-term follow-up guidelines | 0.273165 |
| Cancer J Clin | 0.270171 |
| report | 0.265432 |
| childhood cancer treatment | 0.287484 |
| oncology group | 0.32484 |
| long-term childhood cancer | 0.311378 |
|
CLICK HERE |
| 1985 |
National Cancer Institute |
Html |
es |
Descripción del tratamiento de tumores de encéfalo y de médula espinal infantiles (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento de tumores de encéfalo infantiles. |
| espinal infantiles.ampliar punción | 0.671368 |
| Organización Mundial | 0.330213 |
| células madre | 0.838888 |
| efectos secundarios meses | 0.514746 |
| siguientes aspectos | 0.364078 |
| vÃa oral | 0.337627 |
| encéfalo benignos | 0.752955 |
| PDQ Descripción | 0.372391 |
| efectos tardÃos | 0.660507 |
| PDQ correspondiente | 0.464116 |
| tumor subtipo | 0.432726 |
| PDQ Efectos tardÃos | 0.450037 |
| cáncer.ampliar aspiración | 0.351047 |
| Astrocitoma pilomixoide | 0.336263 |
| lÃquido cefalorraquÃdeo | 0.817195 |
| National Cancer Institute | 0.340319 |
| siguientes riesgos | 0.328861 |
|
| Instituto Nacional | 0.370517 |
| PDQ Tratamiento | 0.975349 |
| riesgo promedio | 0.357023 |
| presente sección | 0.332468 |
| siguientes signos | 0.392336 |
| nuevos tipos | 0.34964 |
| siguientes factores | 0.362333 |
| sistema nervioso central | 0.653419 |
| Physician Data Query | 0.447911 |
| gliomas astroblastoma | 0.333341 |
| pdq correspondiente tipo | 0.412457 |
| alto astrocitoma | 0.3322 |
| panel derecho | 0.358602 |
| espinal infantiles recién | 0.572263 |
| siguientes pruebas | 0.390652 |
| siguientes sumarios | 0.353304 |
| siguientes trastornos | 0.347907 |
|
CLICK HERE |
| 2052 |
National Cancer Institute |
Html |
es |
Terapias biológicas para el cáncer |
Hoja informativa sobre la función del sistema inmunitario; describe la acción de las terapias biológicas. |
| Haluska FG | 0.420038 |
| Redig AJ | 0.419038 |
| ARN mensajero | 0.423865 |
| killer cell-based immunotherapy | 0.432963 |
| células hijas | 0.643617 |
| Canese P | 0.41842 |
| O'Day SJ | 0.419485 |
| clinical applications | 0.420154 |
| we tilt | 0.419245 |
| immune system | 0.418755 |
| altas dosis | 0.418691 |
| linfocitos b | 0.794775 |
| antÃgeno cd52 | 0.453352 |
| Translational Medicine | 0.419593 |
| Comité Asesor | 0.418458 |
| biological therapy | 0.455134 |
| Internal Medicine | 0.419677 |
| Estados Unidos | 0.448833 |
| Expert Opinion | 0.421046 |
| linfocitos t | 0.82421 |
| intrusos foráneos | 0.428976 |
| towards immune-mediated | 0.419994 |
| PubMed Abstract | 0.779921 |
| metastatic melanoma | 0.424461 |
| madre sanas formadoras | 0.440701 |
|
| terapia modificadora | 0.491313 |
| Abeloff's Clinical Oncology | 0.43296 |
| mARN blanco | 0.422446 |
| antÃgeno cd20 | 0.515911 |
| bacteria bacilo | 0.445994 |
| Improved survival with | 0.436486 |
| invasores foráneos | 0.480692 |
| células madre | 0.955075 |
| molécula her-2 | 0.428705 |
| Cancer immunology | 0.420503 |
| Ningún virus | 0.447968 |
| on tumor immunology | 0.437409 |
| McDermott DF | 0.418981 |
| envoltorio protector | 0.421713 |
| IFN)-dependent activation | 0.420375 |
| terapia biológica usa | 0.634008 |
| 90Y‑ibritumomab tiuxetán | 0.424391 |
| ingenierÃa genética | 0.421138 |
| sistema inmunitario. aún | 0.450887 |
| escasa toxicidad | 0.422699 |
| biológica usa organismos | 0.547748 |
| Aún más | 0.468819 |
| virus vector | 0.444624 |
| New England Journal | 0.430623 |
|
CLICK HERE |
| 2972 |
National Cancer Institute |
Video |
en |
Reach out and offer her a helping hand: A Smokefree Pregnancy Video |
We know quitting smoking is tough, and becoming pregnant doesn't suddenly make it easier. "Reach Out & Offer Her a Helping Hand" is intended to rally the American public's support for all mamas-to-be trying to put out the cigs. For more info on how you can help that special lady in your life quit smoking for good, visit: women.smokefree.gov |
| SmokefreeWomen | 0.826013 |
| Healthier Summer Sweets | 0.545266 |
| 04 | 0.327172 |
| women.smokefree.gov | 0.329 |
| NCI Smokefree | 0.680659 |
| Good Night | 0.430291 |
| Positive Environment | 0.433577 |
| life | 0.329079 |
| NCI Smokefree Pregnancy | 0.635056 |
| Challenge | 0.408491 |
| Motivator | 0.335402 |
| American public | 0.460348 |
| smoking | 0.356739 |
| smoke smell | 0.447387 |
| Smokefree Voices Video | 0.623419 |
| Contest | 0.32649 |
| How-to Video | 0.421251 |
| Blog | 0.32681 |
| views | 0.825633 |
| busy schedule | 0.430343 |
|
| info | 0.329188 |
| Helping Hand | 0.601743 |
| Reach | 0.325318 |
| Smokefree Women | 0.817171 |
| Voiceover | 0.330521 |
| Duration | 0.991806 |
| autoplay | 0.374808 |
| NCI Smokefree Women | 0.669737 |
| De-stress | 0.333641 |
| special lady | 0.458682 |
| Offer | 0.359013 |
| Street Team Video | 0.555716 |
| Clean house | 0.432823 |
| newest video | 0.459372 |
| Fitting fitness | 0.42414 |
| visit | 0.325778 |
| cigs | 0.329305 |
| support | 0.329395 |
| Healthy Body Image | 0.533317 |
|
CLICK HERE |
| 3419 |
National Cancer Institute |
Html |
es |
Accidentes en plantas nucleares de electricidad y el riesgo de cáncer |
Hoja informativa acerca de los riesgos del cáncer asociados con accidentes en plantas nucleares de electricidad. Incluye información para pacientes con cáncer que viven en una zona que puede haber sido afectada por un accidente en una planta nuclear. |
| Atomic Radiation | 0.316837 |
| United Nations | 0.364483 |
| accident―An epidemiological perspective | 0.318721 |
| Zablotska L | 0.256274 |
| assembly with scientific | 0.304698 |
| Chernobyl-related thyroid | 0.281728 |
| Nations Scientific Committee | 0.309452 |
| Ulanovsky AV | 0.266554 |
| case-control study | 0.27312 |
| Brenner AV | 0.261036 |
| altas dosis | 0.502454 |
| Health effects | 0.274048 |
| Cardis E | 0.255707 |
| Hatch M | 0.715405 |
| Instituto Nacional | 0.562168 |
| consecuente exposición | 0.36176 |
| related disorders among | 0.314284 |
| Chernobyl nuclear power | 0.336354 |
| causa cáncer | 0.40919 |
| Life Span Study | 0.319261 |
| Mykola DT | 0.263715 |
| Environmental Health Perspectives | 0.308221 |
| PubMed Abstract | 0.845077 |
| Finch SC | 0.258873 |
| Clinical Oncology | 0.262917 |
|
| Bouville A | 0.255535 |
| Chernobyl disaster | 0.278477 |
| Annex D | 0.255425 |
| Epidemiologic Reviews | 0.264619 |
| Amenaza Radiológica | 0.258735 |
| Individual thyroid | 0.27723 |
| workers from ukraine | 0.329042 |
| inhalar partÃculas | 0.413261 |
| Drozdovitch VV | 0.265349 |
| Ukraine related | 0.277279 |
| Ukranian-American study | 0.271859 |
| Contributions from long-lived | 0.322355 |
| quimioterapia sistémica | 0.267728 |
| Ionizing Radiation | 0.316029 |
| incident thyroid cancers | 0.332215 |
| Health Physics | 0.266767 |
| Chornobyl accident | 0.268808 |
| Ciencias Demográficas | 0.257571 |
| Belarus—part II | 0.255864 |
| thyroid cancers | 0.38621 |
| manejo médico | 0.356172 |
| medio ambiente | 0.973732 |
| Minenko VF | 0.264858 |
| Segunda Guerra Mundial | 0.28983 |
|
CLICK HERE |
| 3551 |
National Cancer Institute |
Html |
en |
Cancer Statistics |
Basic information about cancer statistics in the U.S. and how they are used to understand the impact of cancer on society and to develop strategies that address the challenges that cancer poses. |
| cancer statistics | 0.699332 |
| major impact | 0.569457 |
| new screening test | 0.610486 |
| United States | 0.848591 |
| Asian/Pacific Islander women | 0.623563 |
| cancer death rate | 0.734611 |
| cancer deaths | 0.662668 |
| thyroid cancer | 0.618391 |
| SEER program website | 0.613262 |
| renal pelvis cancer | 0.675159 |
| population-based cancer registries | 0.661094 |
| African American men | 0.620993 |
| number | 0.579668 |
| new cancer cases | 0.74726 |
| American Cancer Society | 0.655347 |
| pancreatic cancer | 0.619919 |
| bladder cancer | 0.619451 |
| cancer-related deaths | 0.575865 |
| average age | 0.568157 |
| individual cancer types | 0.652597 |
| North American Association | 0.605716 |
| racial/ethnic group | 0.570832 |
| cancer care | 0.615369 |
| cancer diagnosis | 0.664799 |
|
| breast cancer | 0.617639 |
| rectum cancer | 0.622513 |
| large groups | 0.569141 |
| risk factor | 0.614571 |
| U.S. population | 0.610565 |
| people | 0.571698 |
| statistical trends | 0.613522 |
| age-adjusted mortality | 0.572947 |
| prostate cancer | 0.619132 |
| bronchus cancer | 0.62075 |
| Central Cancer Registries | 0.654709 |
| cancer survivors | 0.603772 |
| cancer mortality | 0.652323 |
| policy makers | 0.566593 |
| Understanding Cancer Prognosis | 0.676403 |
| endometrial cancer | 0.620993 |
| cancer | 0.951216 |
| new cases | 0.679157 |
| cancer incidence | 0.694185 |
| cancer death rates | 0.665983 |
| SEER Cancer Statistics | 0.665479 |
| overall cancer death | 0.735155 |
| cancer rates | 0.609223 |
|
CLICK HERE |
| 14601 |
National Cancer Institute |
Html |
en |
Childhood Vascular Tumors Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of childhood vascular tumors. |
| lesions | 0.459907 |
| body | 0.444762 |
| PDQ cancer information | 0.428885 |
| steroid therapy | 0.431929 |
| malignant tumors | 0.409372 |
| clinical trials | 0.622735 |
| aggressive vascular tumors | 0.43708 |
| congenital hemangioma | 0.425723 |
| cancer information summary | 0.40263 |
| Diagnostic Tests | 0.677407 |
| liver | 0.469914 |
| lobular capillary hemangioma | 0.410892 |
| blood vessels | 0.494734 |
| pyogenic granuloma | 0.401485 |
| diffuse tumors | 0.399482 |
| benign vascular tumor | 0.531292 |
| vascular tumors | 0.851122 |
| clinical trial | 0.485314 |
| spindle cell hemangiomas | 0.4591 |
| malignant vascular tumors | 0.461238 |
| radiation therapy | 0.585507 |
| following | 0.416254 |
| late effects | 0.40785 |
| General Information section | 0.953371 |
|
| treatment | 0.883924 |
| blood vessel | 0.40513 |
| childhood vascular tumor | 0.423751 |
| skin | 0.519128 |
| vascular tumor | 0.671886 |
| benign vascular tumors | 0.586046 |
| infantile hemangiomas | 0.495631 |
| signs | 0.415044 |
| treatment clinical trials | 0.412572 |
| procedures | 0.39986 |
| multiple lesions | 0.412762 |
| tumor cells | 0.435841 |
| new treatment | 0.424941 |
| topical beta-blocker therapy | 0.421578 |
| kaposiform hemangioendothelioma | 0.442163 |
| hemangiomas | 0.524006 |
| risk factor | 0.415027 |
| childhood vascular tumors | 0.50237 |
| benign tumors | 0.412061 |
| blood vessel tumors | 0.39943 |
| kaposi sarcoma | 0.437901 |
| standard treatment | 0.431582 |
| diffuse liver tumors | 0.410968 |
| surgery | 0.449251 |
|
CLICK HERE |